MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy

News & Library

HomeNews & Library
HomeNews & Library

Press releases

May 29, 2020 - MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (Bulevirtide), the First-inClass Entry Inhibitor for the treatment of chronic hepatitis D infections. More...

Scientific Publications

MYR Pharma's scientific founders and collaborators have published numerous papers in top peer reviewed journals describing Myrcludex B mechanism of action and the results of preclinical and clinical development. Myrcludex B has been highlighted in many recent review articles as one of the leading drugs for the treatment of HBV and HDV. More...